Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronavirus01:29

Coronavirus

Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), are enveloped viruses characterized by their single-stranded, positive-sense RNA genome and helical nucleocapsid structure. The hallmark of these viruses is their club-shaped spike (S) glycoproteins that protrude from the viral envelope, facilitating attachment to host cells. Typically, coronaviruses infect the upper respiratory tract, often causing mild or asymptomatic disease. However, certain strains like...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of novel 5' UTR variants for enhanced mRNA translation and vaccine immunogenicity.

Scientific reports·2026
Same author

Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates.

Frontiers in immunology·2026
Same author

Dual Ionizable Lipids (ALC0315 and SM102) in a Novel Lipid Nanoparticle Formulation Enhance In Vivo Delivery and Time-Dependent Expression of Messenger RNA and Self-Amplifying RNA.

ChemMedChem·2026
Same author

Structural basis of influenza A virus neutralization by broadly reactive single-domain antibody G2.3 recognizing glycosylated epitope within hemagglutinin stem domain.

International journal of biological macromolecules·2026
Same author

Modulator therapy: rates and stages of respiratory bacteriome restoration in cystic fibrosis patients chronically infected with Pseudomonadota.

BMC pulmonary medicine·2026
Same author

Circular mRNA against CleanCap linear mRNA vectors: comprehensive comparison, expression, active and passive immunization.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jul 8, 2026

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

4.8K

Ultra-potent RBM-specific single-domain antibody broadly neutralizes multiple SARS-CoV-2 variants with picomolar

Dmitry V Shcheblyakov1, Irina A Favorskaya1, Inna V Dolzhikova1

  • 1Federal State Budget Institution "National Research Center for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya" of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia.

International Journal of Biological Macromolecules
|June 21, 2025
PubMed
Summary

A new single-domain antibody, 1p1B10, shows broad neutralization against numerous SARS-CoV-2 variants, including Omicron sublineages. This antibody offers a promising therapeutic candidate for treating COVID-19 by blocking viral entry into cells.

Keywords:
COVID-19Monoclonal antibodyNeutralizing activityNeutralizing antibodySingle-domain antibodyStructural analysisTherapeutic efficacy

More Related Videos

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
07:44

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

3.2K
Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques
08:07

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Published on: January 12, 2024

857

Related Experiment Videos

Last Updated: Jul 8, 2026

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

4.8K
Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
07:44

Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter

Published on: August 12, 2021

3.2K
Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques
08:07

Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques

Published on: January 12, 2024

857

Area of Science:

  • Virology
  • Immunology
  • Structural Biology

Background:

  • SARS-CoV-2 infection causes severe illness, particularly in high-risk groups, with limited antiviral options.
  • Emerging SARS-CoV-2 variants with numerous mutations pose significant challenges for therapeutic development.

Purpose of the Study:

  • To describe a broadly neutralizing single-domain antibody, 1p1B10, with potent activity against diverse SARS-CoV-2 variants.
  • To elucidate the mechanism of action for the broad neutralizing activity of 1p1B10.

Main Methods:

  • Characterization of 1p1B10 antibody activity against multiple SARS-CoV-2 variants.
  • High-resolution crystal structure determination of the S-protein Receptor Binding Domain (RBD) complexed with 1p1B10.
  • In vivo efficacy studies in Syrian hamsters and hACE2 mice.

Main Results:

  • 1p1B10 demonstrated picomolar activity against a wide range of SARS-CoV-2 variants, including Omicron sublineages (e.g., XBB.1, JN.1).
  • Structural analysis revealed that 1p1B10 binds the RBD, unaffected by mutations, and competes with ACE2 receptor binding.
  • Therapeutic administration of 1p1B10-Fc reduced viral load in hamsters and protected mice from lethal infection.

Conclusions:

  • 1p1B10 exhibits broad neutralizing activity against current and emerging SARS-CoV-2 variants.
  • The antibody's mechanism involves blocking viral attachment via ACE2 receptor competition.
  • 1p1B10 is a promising candidate for the etiotropic treatment of COVID-19.